DMDaniela Markovic

Daniela Markovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniela Markovic has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of a Rapid Immunoassay for Molecular Subphenotype Classification in Pediatric Acute Cardiorespiratory Failure

    by Colin J. Sallee, Clove S. Taylor, Matt S. Zinter, Daniela Markovic, Michelle J. Lim, Ana Costa Monteiro, Ruth Cortado, Andreas Schwingshackl, Michael Agus, Michael Matthay, et al.

    OBJECTIVES: Molecular subphenotypes, identified through latent class analysis (LCA) of biomarker profiles, have the potential to guide targeted therapeutics in critical care. We have previously published that intensive insulin management has subphenotype-specific beneficial effects among children with hyperglycemia accompanying cardiorespiratory failure. However, the real-time application of subphenotype-based strategies in clinical settings remains challenging due to the operational aspects of biomarker assays. Our study had three objectives: 1) to compare biomarker measurements from rapid immunoassay and conventional multiplex platforms; 2) to evaluate the cross-platform transportability of a conventional assay-based parsimonious classifier for LCA-derived subphenotypes and compare it with a classifier trained directly on rapid immunoassay data; and 3) to assess the prognostic and predictive significance of rapid immunoassay-based subphenotypes. DESIGN: Retrospective cohort study. SETTING: Multicenter PICUs. PATIENTS: Two hundred sixty-nine critically ill children with acute cardiorespiratory failure and hyperglycemia (2012–2016). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: LCA was previously used to derive hyperinflammatory and hypoinflammatory classes using a conventional multiplex assay of 13 plasma biomarkers. After feature selection, a parsimonious classifier using interleukin (IL)-6, IL-8, and soluble tumor necrosis factor receptor 1 (sTNFR-1) was developed to predict LCA-derived subphenotypes. We applied this classifier to rapid immunoassay biomarker measurements, yielding an area under the receiver operating characteristic curve (AUROC) of 0.90 (95% CI, 0.85–0.95). However, calibration was poor due to systematic underestimation of sTNFR-1 concentrations by the rapid platform. We then derived and internally validated via bootstrapping a de novo classifier using rapid immunoassay data, achieving an AUROC of 0.90 (95% CI, 0.86–0.95) and excellent calibration. Using a probability threshold of ≥ 0.5, the de novo classifier matched LCA-derived classifications in 241 of 269 cases (accuracy 89.6%). Rapid immunoassay-based subphenotypes demonstrated differences in mortality (33.3% in hyperinflammatory vs. 11.8% in hypoinflammatory; p = 0.009) and differential response to intensive insulin management (interaction p = 0.024). CONCLUSIONS: A parsimonious, rapid immunoassay-based classifier can approximate LCA-derived molecular subphenotypes while preserving their prognostic and predictive significance, with the potential to inform future subphenotype-based precision trials.

  • Incident Stroke in the United States and Foreign Born Black Individuals.

    by Alejandro Vargas, Bruce Ovbiagele, Daniela Markovic, Amytis Towfighi

    There is a paucity of information about the association between nativity and stroke prevalence among Black individuals in the United States. We assessed stroke prevalence among individuals who identified as Black in the 2000-2018 National Health Interview Survey. Respondents were stratified by age (25-55 or 56-74 years) and location of birth (United States; Caribbean, South, and Central America [CSCA]; and Africa). Factors associated with stroke prevalence were assessed using logistic regression, adjusting for sociodemographic and medical characteristics. Among 64,717 respondents who identified as Black, 88.3% were born in the United States, 8.0% were born in CSCA, and 3.7% were born in Africa. Prevalence of stroke was 4.3%, 1.5% and 0.8%, respectively. Foreign born individuals had lower odds of stroke (adjusted OR 0.44, 0.34-0.57 for CSCA and 0.39, 0.23-0.63 for Africa). The odds of stroke were lowest for those who had recently immigrated at the time of the survey (adjusted OR < 15 years 0.27, 95% CI 0.15-0.47). Among individuals who identify as Black, there may be a healthy immigrant effect. Homogenizing racial and ethnic groups may mask key epidemiologic trends and limit targeted interventions.

  • Effects of Allostatic Load on Long-Term Survival After Stroke

    by Nicole Betty Johnson, Erica M. Jones, Bruce Ovbiagele, Daniela Markovic, Amytis Towfighi

    BACKGROUND: Allostatic load index (ALI) is often utilized to quantify the physiological response to stress. This study assesses the relationship between ALI and its impact on all-cause, cardiovascular, and stroke mortality in individuals with a self-reported history of stroke and within the general National Health and Nutritional Examination Survey sampled population. METHODS: Using data from the National Health and Nutritional Examination Survey (III, 1988–1994) and the 2015 Linked Mortality File, we selected adults aged ≥25 years with self-reported stroke. We computed the weighted prevalence of each ALI category to obtain nationally representative estimates with higher ALI corresponding to a higher stress burden. We evaluated the relationship between ALI category and mortality outcomes using the Cox proportional hazard model, considering the survey design variables and adjusting for age, sex, race/ethnicity, education, marital status, income, drinking, and smoking status. RESULTS: Of 17 284 people screened in the National Health and Nutritional Examination Survey sample population, 15 567 individuals were included in the study. The ALI distribution was 48.3% ALI ≤1, 21.7% ALI=2, and 30% ALI ≥3. Of 414 individuals with a reported history of stroke, there were 11.8% ALI ≤1, 22.1% ALI=2, and 66.1% ALI ≥3. There was an association between a higher ALI and older age, Black and Mexican American race, and >1 comorbidity in the overall sampled population. In the population with prior stroke, those with ALI ≥3 had 2.7× higher adjusted all-cause mortality (hazard ratio, 2.7 [CI, 1.5–4.9]) and 4.5× higher adjusted cardiovascular mortality (hazard ratio, 4.5 [CI, 1.4–14.3]) compared with those with ALI ≤1. In the general sampled National Health and Nutritional Examination Survey population, the ALI ≥3 group had 1.8× higher adjusted stroke mortality (hazard ratio, 1.8 [CI, 1.1–3.1]). CONCLUSIONS: Baseline higher ALI is associated with greater all-cause and cardiovascular mortality in stroke survivors and greater stroke mortality in the overall sampled National Health and Nutritional Examination Survey population.


  • Open Access

    Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease

    by Sangmee Sharon Bae, Fereidoun Abtin, Grace Kim, Daniela Markovic, Cato Chan, Siamak Moghadam-Kia, Chester V Oddis, Daniel Sullivan, Galina Marder, Swamy Venuturupalli, et al.

    Objectives: To explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD). Methods: We analysed 20 patients with antisynthetase antibodies and active ILD enrolled in the Abatacept in Myositis-Associated Interstitial Lung Disease study. High-resolution chest CT was obtained at weeks 0, 24 and 48 and QIA scored the extent of ground glass (quantitative score for ground glass), fibrosis (quantitative score for lung fibrosis, QLF) and total ILD (quantitative ILD, QILD). Mixed-effects models estimated longitudinal QIA scores over time. Associations between QIA scores with clinical/physiological parameters were analysed longitudinally using repeated-measures mixed-effects models. Results: Patients were median age 57 years, 55% males and 85% white. Higher (worse) baseline QIA scores correlated with lower baseline forced vital capacity (FVC) and diffusing capacity adjusted for haemoglobin (DLCO). Longitudinal QIA trajectories trended towards improving scores during the trial, and patients on O2 at baseline had worsening QIA trajectories which were different from patients who were not on O2. Longitudinal QIA scores demonstrated strong associations with both FVC and DLCO over time. Higher QILD scores over time were also associated with worse dyspnoea scores, pulmonary visual analogue scale, physician and patient global disease activity, health status in 6/8 domains of the Short Form-36 and higher oxygen requirements. Patients with significant radiographic improvement at 48 weeks had higher baseline QLF, QILD and worse DLCO. Conclusions: Longitudinal QIA scores associate with lung physiology, patient perception of respiratory status, overall disease activity and quality of life over time in ARS-ILD. QIA may allow reproducible monitoring of disease progression and response to therapy over time. Trial registration number: NCT03215927.


  • The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study

    by Rajat Suri, Daniela Markovic, Han Woo, Mehrdad Arjomandi, R. Graham Barr, Russell P. Bowler, Gerard Criner, Jeffrey L. Curtis, Mark T. Dransfield, M. Bradley Drummond, et al.

    Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have airflow obstruction and maldistribution of ventilation. For those living at high altitude, any gas exchange abnormality is compounded by reduced partial pressures of inspired oxygen. Objectives: Does residence at higher altitude exposure affect COPD outcomes, including lung function, imaging characteristics, symptoms, health status, functional exercise capacity, exacerbations, and mortality? Methods: From the SPIROMICS (Subpopulation and Intermediate Outcome Measures in COPD Study) cohort, we identified individuals with COPD living below 1,000 ft (305 m) elevation (n = 1,367) versus above 4,000 ft (1,219 m) elevation (n = 288). Multivariable regression models were used to evaluate associations of exposure to high altitude with COPD-related outcomes. Measurements and Main Results: Living at higher altitude was associated with reduced functional exercise capacity as defined by 6-minute-walk distance (−32.3 m [95% confidence interval, −49.8 to −14.8 m]). There were no differences in patient-reported outcomes as defined by symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scale), or health status (St. George’s Respiratory Questionnaire). Higher altitude was not associated with a different rate of FEV1 decline. Higher altitude was associated with lower odds of severe exacerbations (incidence rate ratio, 0.65 [95% confidence interval, 0.46 to 0.90]). There were no differences in small airway disease, air trapping, or emphysema. In longitudinal analyses, higher altitude was associated with increased mortality (hazard ratio, 1.25 [95% confidence interval, 1.0 to 1.55]); however, this association was no longer significant when accounting for air pollution. Conclusions: Long-term altitude exposure is associated with reduced functional exercise capacity in individuals with COPD, but this did not translate into differences in symptoms or health status. In addition, long-term high-altitude exposure did not affect progression of disease as defined by longitudinal changes in spirometry. Clinical trial registered with www.clinicaltrials.gov (NCT 01969344).


  • Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease

    by Sangmee Sharon Bae, Daniela Markovic, Didem Saygin, Daniel Sullivan, Koichi Yamaguchi, Siamak Moghadam-Kia, Chester V Oddis, Fereidoun Abtin, Grace Hyun J Kim, Galina Marder, et al.

    Objective: The 6-min walk test (6MWT) is a simple test widely used to assess sub-maximal exercise capacity in chronic respiratory diseases. We explored the relationship of 6-min walk distance (6MWD) with measurements of physiological, clinical, radiographic measures in patients with myositis-associated interstitial lung disease (MA-ILD). Method: We analysed data from the Abatacept in Myositis Associated Interstitial Lung Disease (Attack My-ILD) study, a 48-week multicentre randomized trial of patients with anti-synthetase antibodies and active MA-ILD. 6MWD, forced vital capacity (FVC), diffusing capacity (DLCO), high-resolution CT and various physician-/patient-reported outcome measures were obtained during the trial. Spearman’s correlations and repeated-measures analysis with linear mixed-effects models were used to estimate the associations between 6MWD and various physiologic, clinical and radiographic parameters both cross-sectionally and longitudinally. Results: Twenty participants with a median age of 57 years, 55% male and 85% white were analysed. Baseline 6MWD did not associate with baseline pulmonary function tests. Repeated-measures analysis showed 6MWD over time associated with FVC over time, but not with DLCO. 6MWD over time also correlated with University of California San Diego Shortness of Breath questionnaire dyspnoea score, Borg scores, as well as global disease activity and muscle strength over time. Emotional role functioning, vitality, general health and physical functioning scores by Short Form 36 also correlated with 6MWD over time. Conclusions: Exploratory work in a small cohort of MA-ILD demonstrated 6MWD over time associated with parallel changes in FVC and patient-reported outcomes of dyspnoea, but not with DLCO. Larger studies are needed to validate the reliability, responsiveness and utility of the 6MWT in MA-ILD. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03215927.


  • Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome

    by Lauren Pace, Daniela Markovic, Richard Buyalos, Fernando Bril, Ricardo Azziz

    Context: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged females, and women with PCOS are at increased risk for endometrial cancer (EndoCA), the most common gynecological malignancy. Objective: Our study sought to assess the economic burden associated with EndoCA in PCOS. Method: Using PRISMA systematic review guidelines, we evaluated studies on EndoCA rates in patients with PCOS. Excluded studies were reviews and case reports, those with nonhuman subjects, without controls, without full text available, or reporting solely on other conditions. Selected studies were assessed for quality using the Newcastle-Ottawa Scale. Meta-analysis used DerSimonian-Laird random effects model to assess pooled risk ratio (RR). Excess cost was assessed in US dollars (USD). Result: Of 98 studies screened, 9 were included. Pooled RR for EndoCA in PCOS was 3.46 (95% CI, 2.28-5.23), P ≤ .001. In the United States, prevalence of EndoCA in patients with PCOS in 2020 was 1.712%, compared with a baseline estimated prevalence in all women of 0.489%. The excess prevalence of EndoCA attributable to PCOS was 1.223%, approximately 98 348 affected women. A population attributable fraction of EndoCA for PCOS was 24.4%. Given estimated costs of EndoCA exceeding $1.9 billion (in 2023 USD), the economic burden of EndoCA attributable to PCOS exceeds $467 million/year. Conclusion: The excess annual US healthcare cost for EndoCA attributable to PCOS exceeds $467 million/year (2023 USD). Although a concerning morbidity of PCOS, it is notable that the economic burden of EndoCA attributable to the disorder represents only a small fraction of its total healthcare burden.


  • The link between insurance and blood pressure control in U.S. stroke survivors

    by Daniel M. Oh, Michael McManus, Daniela Markovic, Bruce Ovbiagele, Nerses Sanossian, Amytis Towfighi


  • Temporal Trends in Blood Pressure Awareness, Treatment, and Control Among US Stroke Survivors

    by Daniel M. Oh, Bruce Ovbiagele, Daniela Markovic, Amytis Towfighi


  • Top Cited Papers
    Open Access

    Portable hypothermic oxygenated machine perfusion for organ preservation in liver transplantation: A randomized, open-label, clinical trial

    by Guergana G. Panayotova, Keri E. Lunsford, R. Cutler Iii Quillin, Abbas Rana, Vatche G. Agopian, Grace S. Lee-Riddle, Daniela Markovic, Flavio Paterno, Adam D. Griesemer, Arpit Amin, et al.

    Background and Aims: In liver transplantation, cold preservation induces ischemia, resulting in significant reperfusion injury. Hypothermic oxygenated machine perfusion (HMP-O2) has shown benefits compared to static cold storage (SCS) by limiting ischemia-reperfusion injury. This study reports outcomes using a novel portable HMP-O2 device in the first US randomized control trial. Approach and Results: The PILOT trial (NCT03484455) was a multicenter, randomized, open-label, noninferiority trial, with participants randomized to HMP-O2 or SCS. HMP-O2 livers were preserved using the Lifeport Liver Transporter and Vasosol perfusion solution. The primary outcome was early allograft dysfunction. Noninferiority margin was 7.5%. From April 3, 2019, to July 12, 2022, 179 patients were randomized to HMP-O2 (n=90) or SCS (n=89). The per-protocol cohort included 63 HMP-O2 and 73 SCS. Early allograft dysfunction occurred in 11.1% HMP-O2 (N=7) and 16.4% SCS (N=12). The risk difference between HMP-O2 and SCS was −5.33% (one-sided 95% upper confidence limit of 5.81%), establishing noninferiority. The risk of graft failure as predicted by Liver Graft Assessment Following Transplant score at seven days (L-GrAFT7) was lower with HMP-O2 [median (IQR) 3.4% (2.4–6.5) vs. 4.5% (2.9–9.4), p=0.024]. Primary nonfunction occurred in 2.2% of all SCS (n=3, p=0.10). Biliary strictures occurred in 16.4% SCS (n=12) and 6.3% (n=4) HMP-O2 (p=0.18). Nonanastomotic biliary strictures occurred only in SCS (n=4). Conclusions: HMP-O2 demonstrates safety and noninferior efficacy for liver graft preservation in comparison to SCS. Early allograft failure by L-GrAFT7 was lower in HMP-O2, suggesting improved early clinical function. Recipients of HMP-O2 livers also demonstrated a lower incidence of primary nonfunction and biliary strictures, although this difference did not reach significance.